Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

VA/DoD Guidelines Suggest PPIs, H2-Antagonists Work Equally Well For GERD

Executive Summary

H2-antagonists and proton pump inhibitors work equally well for the initial treatment of gastroesophageal reflux disease, a 1draft guideline on clinical practice from the Departments of Defense and Veterans Affairs states

You may also be interested in...



VA/DoD GERD guideline (correction)

Veteran's Affairs/Department of Defense draft guideline states both proton pump inhibitors and H2-antagonists can be used for initial treatment of gastroesophageal reflux disease. "The Pink Sheet" (1April 21, p. 15) incorrectly suggested that the guidelines consider the two drug classes to be equally effective. Both Johnson & Johnson/Eisai's Aciphex (rabeprazole) and TAP's Prevacid (lansoprazole) are included on the Basic Core Formulary...

VA/DoD GERD guideline (correction)

Veteran's Affairs/Department of Defense draft guideline states both proton pump inhibitors and H2-antagonists can be used for initial treatment of gastroesophageal reflux disease. "The Pink Sheet" (1April 21, p. 15) incorrectly suggested that the guidelines consider the two drug classes to be equally effective. Both Johnson & Johnson/Eisai's Aciphex (rabeprazole) and TAP's Prevacid (lansoprazole) are included on the Basic Core Formulary...

DoD/VA Allegra Price Is One-Third Of AWP; Joint Procurement Expands

The Departments of Defense and Veterans Affairs have awarded a joint national procurement contract to Aventis' Allegra (fexofenadine) for approximately one-third the average wholesale price.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS041676

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel